Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Fierce Pharma
Wed, 03/29/17 - 10:40 pm
Tags:
Gilead Sciences, Harvoni, drug ads, DTC ads, hepatitis C
3 Drugmakers With Boatloads of Cash to Spend
Motley Fool
Wed, 03/29/17 - 04:54 pm
Tags:
Pfizer, Gilead Sciences, Amgen, JNJ, M&A
Rahul Garg Says Trump's Tweets About Drug Prices Have Made Gilead A Buy
Forbes
Tue, 03/28/17 - 11:50 pm
Tags:
Donald Trump, drug pricing, social media, twitter, Gilead Sciences
Gilead hepatitis C drug patent faces European challenge
Yahoo/Reuters
Mon, 03/27/17 - 09:47 am
Tags:
Gilead Sciences, hepatitis C, Europe, sofosbuvir
Biotechs Back in the Doghouse After Failed Rally
Investopedia
Thu, 03/23/17 - 09:57 pm
Tags:
biotech, Gilead Sciences, Amgen
Wait, Gilead Might Actually Hit Its 1st Quarter Numbers?!?!
Barron's
Wed, 03/15/17 - 10:35 am
Tags:
Gilead Sciences, earnings
Gilead Sciences: Is an Incyte Deal ‘Reasonable’?
Barron's
Mon, 03/13/17 - 11:26 am
Tags:
Gilead Sciences, Incyte, M&A
The new CEOs in biopharma are joining the big players at the billion-dollar chip table
Endpoints
Fri, 03/10/17 - 09:16 pm
Tags:
Pharma CEOs, M&A, Eli Lilly, David Ricks, CoLucid Pharmaceuticals, Celgene, Gilead Sciences, GSK, Biogen
What Does Gilead Need? Stable HCV Scripts and “a String of Pearls”
Barron's
Fri, 03/10/17 - 09:52 am
Tags:
Gilead Sciences, hepatitis C
In quick rebuttal, Express Scripts blasts Gilead exec's pricing blame
Fierce Pharma
Wed, 03/8/17 - 10:42 am
Tags:
Express Scripts, Gilead Sciences, drug pricing, PBMs
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Motley Fool
Tue, 03/7/17 - 11:17 am
Tags:
Gilead Sciences, HIV, hepatitis C
Gilead Executive Says Pharmacy Benefit Managers Keep Prices High
Bloomberg
Fri, 03/3/17 - 10:29 pm
Tags:
Gilead Sciences, PBMs, drug pricing
These HIV Regimens Are Expected to See Solid Global Demand in 2017
Market Realist
Fri, 02/24/17 - 09:18 am
Tags:
Gilead Sciences, Pfizer, GSK, JNJ, tenofovir
Making (good) deals is hard to do, Gilead CEO says, but he's working on it
Fierce Pharma
Fri, 02/24/17 - 09:12 am
Tags:
Gilead Sciences, M&A, Pharma CEOs, John Milligan
This Strategy Could Boost GILD’s HIV Franchise Revenue in 2017
Market Realist
Thu, 02/23/17 - 09:47 pm
Tags:
Gilead Sciences, HIV
Top 10 U.S. patent losses of 2017
Fierce Pharma
Thu, 02/23/17 - 09:29 am
Tags:
patents, Copaxone, Cialis, Viagra, Velcade, Sustiva, Sandostatin LAR, Norditropin, Viread, Pristiq, Strattera, Pfizer, Teva, Takeda, Eli Lilly, Novartis, Bristol-Myers Squibb, Novo Nordisk, Gilead Sciences
Gilead pushes hep C testing in baby boomers as its blockbusters plummet
Fierce Pharma
Thu, 02/23/17 - 09:21 am
Tags:
Gilead Sciences, hepatitis C, baby boomers, DTC advertising, Harvoni, Sovaldi
3 Things Gilead Sciences' CEO Just Said That You'll Want to Know
Motley Fool
Wed, 02/22/17 - 05:10 pm
Tags:
Gilead Sciences, Pharma CEOs, John Milligan, hepatitis C, HIV, M&A
Sarepta Sells Priority Review Voucher for $125M
Investopedia
Tue, 02/21/17 - 12:23 pm
Tags:
Sarepta Therapeutics, Gilead Sciences, priority review, FDA
Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well
Endpoints
Sat, 02/18/17 - 02:21 pm
Tags:
Gilead Sciences, addiction, GS-6637, CV Therapeutics

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.